Efficacy Analysis Of Long-term Systematic And Unsystematic Follow-up For Patients With Chronic Hepatitis B In Yanbian Area

Objective:To retrospectively analyze the differences of related indicators and prognosis of patients with chronic hepatitis B(CHB)in Yanbian area after long-term systematic and non systematic follow-up,so as to adequate medical treatment for patients with CHB in this area.Method:A long-term systematic follow-up group was selected from 90 patients with CHB who were initially treated in Yanbian area from 2013 to 2015 and included in the"13th five year plan"national major science and technology special project"the effect of long-term antiviral therapy on the reversal and long-term prognosis of hepatitis B liver fibrosis/cirrhosis";During this period,102 CHB patients who applied for chronic disease subsidy for diagnosis and treatment were in the long-term non systematic follow-up group.The clinical data(age,gender,nationality,height,weight,drinking history,smoking history,history of hypertension,history of diabetes,laboratory test indicators and imaging examination)of the two groups before treatment and relevant clinical data after 260 weeks of treatment were collected and analyzed.Result:1.In the long-term systematic follow-up group,the age was 39.92±8.35years old,73.3%were male,and 28(31.1%)had end-stage liver disease;In the long-term non systematic follow-up group,the age was 40.60±10.70 years old,the proportion of males was 74.5%,and 68 patients(66.7%)had end-stage liver disease;There was no difference in age and sex between the two groups(P>0.05);The incidence of end-stage liver disease in the long-term systematic follow-up group was lower than that in the long-term non systematic follow-up group(P<0.05);2.Compared with the long-term non systematic follow-up group,the changes of AST,ALT,TBIL,GGT,APRI,GPR,FIB-4,ALT,AST,APRI,GPR and FIB-4 in the long-term systematic follow-up group were lower,and the ALB level was higher(P<0.05).3.After 260 weeks of systematic follow-up,the proportion of HBV DNA quantitative test value<1.0?10~3IU/ml in the long-term systematic follow-up group was significantly higher than that in the long-term non systematic follow-up group,and the HBe Ag negative rate in the long-term systematic follow-up group was significantly higher than that in the long-term non systematic follow-up group(P<0.05).Conclusion:1.Long term systematic follow-up can significantly reduce the risk of end-stage liver disease,but can not completely prevent the occurrence of end-stage liver disease.2.Compared with the long-term non-systematic follow-up group,the long-term systematic follow-up group was superior to the long-term non-systematic follow-up group in terms of HBV DNA inhibition,liver function improvement,and liver fibrosis score improvement.